




RealRate

PHARMACEUTICAL 2023

Petros Pharmaceuticals Inc
Rank 290 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Petros Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Petros Pharmaceuticals Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Petros Pharmaceuticals Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is 204%, being 41% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	14,668
Cost of Goods Sold	2,289
Intangible Assets	12,244
Liabilities, Current	7,068
Liabilities, Non-Current	263
Other Assets	5,470
Other Compr. Net Income	0
Other Expenses	10,265
Other Liabilities	8,388
Other Net Income	474
Other Revenues	5,992
Property and Equipment	39
Research and Development	1,740
Selling, General and Administrative Expense	12,209

Output Variable	Value in 1000 USD
Assets	32,421
Liabilities	15,719
Expenses	26,504
Revenues	5,992
Stockholders Equity	16,702
Net Income	-20,038
Comprehensive Net Income	-20,038
BaseVar	40,555
ECR before Limited Liability	68%
Economic Capital Ratio	204%